| A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop KE Ware, TK Hinz, E Kleczko, KR Singleton, LA Marek, BA Helfrich, ... Oncogenesis 2 (3), e39-e39, 2013 | 256 | 2013 |
| Systematic identification of signaling pathways with potential to confer anticancer drug resistance CA Martz, KA Ottina, KR Singleton, JS Jasper, SE Wardell, ... Science signaling 7 (357), ra121-ra121, 2014 | 225 | 2014 |
| Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells ME Marshall, TK Hinz, SA Kono, KR Singleton, B Bichon, KE Ware, ... Clinical cancer research 17 (15), 5016-5025, 2011 | 116 | 2011 |
| Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence KR Singleton, L Crawford, E Tsui, HE Manchester, O Maertens, X Liu, ... Cell reports 21 (10), 2796-2812, 2017 | 102 | 2017 |
| Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC KR Singleton, TK Hinz, EK Kleczko, LA Marek, J Kwak, T Harp, J Kim, ... Cancer research 75 (20), 4398-4406, 2015 | 66 | 2015 |
| Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer KH Lin, JC Rutter, A Xie, B Pardieu, ET Winn, RD Bello, A Forget, ... Nature genetics 52 (4), 408-417, 2020 | 57 | 2020 |
| A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 … KR Singleton, J Kim, TK Hinz, LA Marek, M Casás-Selves, C Hatheway, ... Molecular pharmacology 83 (4), 882-893, 2013 | 48 | 2013 |
| Elevated extracellular K+ inhibits apoptosis of corneal epithelial cells exposed to UV-B radiation KR Singleton, DS Will, MP Schotanus, LD Haarsma, LR Koetje, ... Experimental eye research 89 (2), 140-151, 2009 | 31 | 2009 |
| Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy J Kim, VT Vasu, R Mishra, KR Singleton, M Yoo, SM Leach, ... Bioinformatics 30 (17), 2393-2398, 2014 | 27 | 2014 |
| ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer AB Pilling, J Kim, A Estrada-Bernal, Q Zhou, AT Le, KR Singleton, ... Oncotarget 9 (10), 8823, 2018 | 23 | 2018 |
| Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis MV Liberti, AE Allen, V Ramesh, Z Dai, KR Singleton, Z Guo, JO Liu, ... Journal of Biological Chemistry 295 (1), 111-124, 2020 | 14 | 2020 |
| An inducible TGF-β2-TGFβR pathway modulates the sensitivity of HNSCC cells to tyrosine kinase inhibitors targeting dominant receptor tyrosine kinases EK Kleczko, J Kim, SB Keysar, LR Heasley, JR Eagles, M Simon, ... PLoS One 10 (5), e0123600, 2015 | 12 | 2015 |
| Discrete-time term structure models with generalized market prices of risk Q Dai, A Le, K Singleton working paper, 2006 | 10 | 2006 |
| Drug dependence in cancer is exploitable by optimally constructed treatment holidays J Maltas, ST Killarney, KR Singleton, MAR Strobl, R Washart, KC Wood, ... Nature ecology & evolution 8 (1), 147-162, 2024 | 8 | 2024 |
| Functional RNAi screens define distinct protein kinase vulnerabilities in EGFR-dependent HNSCC cell lines TK Hinz, EK Kleczko, KR Singleton, J Calhoun, LA Marek, J Kim, AC Tan, ... Molecular Pharmacology 96 (6), 862-870, 2019 | 7 | 2019 |
| Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes KR Singleton, KC Wood Genes & Cancer 7 (7-8), 218, 2016 | 6 | 2016 |
| Analysis of drug resistance using kinome-wide functional screens KR Singleton, KT Earley, LE Heasley Kinase Signaling Networks, 163-177, 2017 | 3 | 2017 |
| A Receptor Tyrosine Kinase Network Comprised of FGFRs, EGFR, ERBB2 and MET Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines KR Singleton, J Kim, TK Hinz, LA Marek, M Casas-Selves, C Hatheway, ... Molecular Pharmacology, 2013 | 3 | 2013 |
| Evolved resistance to GAPDH inhibition results in loss of the Warburg Effect but retains a different state of glycolysis MV Liberti, AE Allen, V Ramesh, Z Dai, KR Singleton, Z Guo, JO Liu, ... bioRxiv, 602557, 2019 | 1 | 2019 |
| ALK-driven lung cancer: potential therapeutic strategies for treatment and prevention of drug resistance AB Pilling, AT Le, AC Tan, J Kim, KR Singleton, LE Heasley, B Helfrich, ... Cancer Research 72 (8_Supplement), 5594-5594, 2012 | 1 | 2012 |
